Research programme: mescaline derivatives - Enveric Biosciences
Latest Information Update: 26 Oct 2021
Price :
$50 *
At a glance
- Originator MagicMed Industries
- Developer Enveric Biosciences
- Class Alkaloids; Antipsychotics; Neuropsychotherapeutics; Phenethylamines; Phenyl ethers
- Mechanism of Action Serotonin 5-HT2 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Mental disorders; Neurological disorders
Most Recent Events
- 24 May 2021 Enveric Biosciences enters into definitive agreement to acquire MagicMed Industries
- 24 May 2021 Mescaline derivative - MagicMed Industries is available for licensing as of 09 Jun 2021. https://www.magicmedindustries.com/about-us/
- 24 May 2021 MagicMed Therapeutics has patents pending for derivatives of mescaline